11:30 - 11:45 a.m., S406 - Vista Room
-- Activity of sorafenib (SOR) in patients (pts) with imatinib (IM) and
sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST):
A phase II trial of the University of Chicago Phase II Consortium
-- Lauren Wiebe, MD, fellow, University of Chicago, Chicago, IL
-- Abstract #10502, oral presentation, Saturday, May 31, 2008,
8:45 - 9 a.m. W375d
-- A Phase II study of sorafenib in metastatic thyroid carcinoma
-- Marcia S. Brose, MD, PhD, assistant professor, director of cancer
genetics laboratory, University of Pennsylvania Health System,
-- Poster 18, abstract #6026, poster discussion, Sunday, June 1, 2008,
8 a.m. - 12 p.m., E450b
"Along with international study groups and investigators, Bayer and Onyx are committed to a comprehensive clinical trial program evaluating Nexavar for additional types of cancer including lung cancer, breast cancer, melanoma and adjuvant use in kidney cancer," Susan Kelley, MD, vice president, Therapeutic Area Oncology, Bayer HealthCare Pharmaceuticals. "With its proven track record in two cancers, dual-targeted mechanism and proven tolerability, we continue to identify important new areas where Nexavar may provide clinical benefit for people affected by cancer."
Nexavar's Differentiated Mechanism
Nexavar targets both the tumor cell and tumor vasculature. In preclinical studies, Nexavar has been shown to target members of two classes of kinases known to be involved in both cell proliferation (growth) and angiogenesis (blood supply) -- two important processes that enable cancer growth. These kinases included Raf kinase, VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-B, KIT, FLT-3 and RET.
Nexavar is currently approved in more than 40 countries for the
treatment of patients with unresectable live
|SOURCE Bayer HealthCare Pharmaceuticals, Inc.; OnyxPharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved